http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
-
I-Mab Announces Acceptance of IND Application from China NMPA for Phase 2 Clinical Trial of Enoblituzumab in Combination with Pembrolizumab in Solid Tumors
-
Zai Lab (ZLAB) and MacroGenics (MGNX) Enter Pact to Develop and Commercialize Preclinical Bispecific Antibodies in Oncology
-
Macrogenics (MGNX), Zai Lab Enter Into Broad Strategic Collaboration to Develop and Commercialize Preclinical Bispecific Antibodies in Oncology
-
MacroGenics and Zai Lab Enter Into Broad Strategic Collaboration to Develop and Commercialize Preclinical Bispecific Antibodies in Oncology
-
MacroGenics and Zai Lab Enter Into Broad Strategic Collaboration to Develop and Commercialize Preclinical Bispecific Antibodies in Oncology
-
Zai Lab and MacroGenics Enter Into Broad Strategic Collaboration to Develop and Commercialize Preclinical Bispecific Antibodies in Oncology
-
Zai Lab and MacroGenics Enter Into Broad Strategic Collaboration to Develop and Commercialize Preclinical Bispecific Antibodies in Oncology
-
Zai Lab Partner MacroGenics Announces FDA Approval of MARGENZA™ for Patients with Pretreated Metastatic HER2-Positive Breast Cancer
-
Zai Lab Partner MacroGenics Announces FDA Approval of MARGENZA™ for Patients with Pretreated Metastatic HER2-Positive Breast Cancer
-
MacroGenics and EVERSANA Announce Agreement to Support the Potential Launch and Commercialization of Margetuximab
-
MacroGenics and EVERSANA Announce Agreement to Support the Potential Launch and Commercialization of Margetuximab
-
Notice of Lead Plaintiff Deadline for Shareholders in the Macrogenics, Inc. Securities Class Action Lawsuit
-
Incyte (INCY) and MacroGenics (MGNX) Enter Pact on Anti-PD-1 Monoclonal Antibody MGA012
-
Incyte and MacroGenics Announce Global Collaboration and Licensing Agreement for Anti-PD-1 Monoclonal Antibody MGA012
-
MacroGenics and Merck to Collaborate on Immuno-Oncology Study Evaluating Margetuximab in Combination with KEYTRUDA(R) (pembrolizumab) for Advanced Gastric Cancer
-
Griffin's Blue Ridge Capital 13F Shows New MasterCard (MA), Visa (V) Stakes (more...)
-
Griffin's Blue Ridge Capital Shows New Stakes in Allegion (ALLE), Castlight Health (CSLT), Myriad Genetics (MYGN), Walgreen (WAG) (more...)
-
Blue Ridge Capital Enters Apple (AAPL), Twitter (TWTR) (more...)